Neurocrine Biosciences (NBIX) 10-Q 29 Oct 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Oct. 23, 2013
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	30-Sep-13
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q3
Trading Symbol	NBIX
Entity Registrant Name	NEUROCRINE BIOSCIENCES INC
Entity Central Index Key	914475
Current Fiscal Year End Date	-19
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		67,343,394

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$34,889	$63,754
Short-term investments, available for sale	122,022	109,259
Receivables under collaboration agreements	75	14,089
Other current assets	2,232	2,162
Total current assets	159,218	189,264
Property and equipment, net	1,739	1,900
Long-term investments	675	480
Restricted cash	4,335	4,335
Total assets	165,967	195,979
Current liabilities:
Accounts payable	1,097	911
Accrued liabilities	7,882	8,094
Current portion of deferred revenues	730	2,919
Current portion of cease-use liability	409	589
Current portion of deferred gain on sale of real estate	3,203	3,133
Total current liabilities	13,321	15,646
Deferred gain on sale of real estate	18,458	20,872
Deferred rent	1,955	1,840
Cease-use liability	2,789	3,097
Other liabilities	152	152
Total liabilities	36,675	41,607
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value; 110,000,000 shares authorized; issued and outstanding shares were 67,343,207 as of September 30, 2013 and 66,446,888 as of December 31, 2012	67	66
Additional paid-in capital	884,355	873,981
Accumulated other comprehensive loss	-9	-2
Accumulated deficit	-755,121	-719,673
Total stockholders' equity	129,292	154,372
Total liabilities and stockholders' equity	$165,967	$195,979

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Statement Of Financial Position [Abstract]
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	110,000,000	110,000,000
Common stock, issued	67,343,207	66,446,888
Common stock, outstanding	67,343,207	66,446,888

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenues:
Sponsored research and development		$1,369		$4,938
License fees	729	7,988	2,189	26,255
Total revenues	729	9,357	2,189	31,193
Operating expenses:
Research and development	9,490	9,860	30,330	28,066
General and administrative	3,245	3,324	10,007	10,126
Cease-use expense		135		135
Total operating expenses	12,735	13,319	40,337	38,327
Loss from operations	-12,006	-3,962	-38,148	-7,134
Other income:
Gain on sale/disposal of assets	6		38	25
Deferred gain on real estate	781	759	2,344	2,276
Investment income, net	93	123	317	359
Other (loss) income, net	-5	2	1	9
Total other income	875	884	2,700	2,669
Net loss	-11,131	-3,078	-35,448	-4,465
Net loss per common share:
Basic and diluted	($0.17)	($0.05)	($0.53)	($0.07)
Shares used in the calculation of net loss per common share:
Basic and diluted	67,199	66,342	66,868	65,355
Other comprehensive loss:
Net loss	-11,131	-3,078	-35,448	-4,465
Net unrealized gains (losses) on available-for-sale securities	35	162	-7	106
Comprehensive loss	($11,096)	($2,916)	($35,455)	($4,359)

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	($35,448)	($4,465)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	515	481
Gain on sale of assets	-2,382	-2,301
Cease-use expense		135
Deferred revenues	-2,189	-26,256
Deferred rent	115	238
Amortization of premiums on investments	2,108	2,480
Non-cash share-based compensation expense	5,123	4,169
Change in operating assets and liabilities:
Receivables under collaboration agreements and other assets	13,944	-684
Accounts payable and accrued liabilities	-26	-16
Cease-use liability	-488	-193
Other liabilities		27
Net cash used in operating activities	-18,728	-26,385
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of investments	-130,379	-139,505
Sales and maturities of investments	115,306	77,789
Proceeds from sales of property and equipment	38	25
Deposits and restricted cash		-28
Purchases of property and equipment	-354	-929
Net cash used in investing activities	-15,389	-62,648
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of common stock	5,252	83,414
Net cash provided by financing activities	5,252	83,414
Net decrease in cash and cash equivalents	-28,865	-5,619
Cash and cash equivalents at beginning of the period	63,754	50,107
Cash and cash equivalents at end of the period	$34,889	$44,488

ORGANIZATION_AND_SIGNIFICANT_A

ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]
ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES	1. ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES
	Description of Business. Neurocrine Biosciences, Inc. (the Company or Neurocrine) is a clinical stage drug discovery company primarily focused on neurological and endocrine based diseases and disorders. The Company discovers and develops innovative pharmaceuticals, in diseases with high unmet medical needs or where the existing drug classes are inadequate, through a disciplined yet entrepreneurial process. Utilizing a portfolio approach to drug discovery, the Company has multiple small molecule drug candidates at various stages of pharmaceutical development. The Company develops proprietary pharmaceuticals for its pipeline, as well as collaborating with other pharmaceutical companies on its discoveries. The Company’s two lead late stage clinical programs are elagolix, a GnRH antagonist for women’s health that is partnered with AbbVie Inc., and a wholly owned VMAT2 inhibitor for the treatment of movement disorders.
	Basis of Presentation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial information and with the instructions of the Securities and Exchange Commission (SEC) on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of the Company’s financial position and of the results of operations and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary.
	These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2012 included in the Company’s Annual Report on Form 10-K filed with the SEC. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year. The balance sheet at December 31, 2012 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.
	Impact of Recently Issued Accounting Standards. In February 2013, the Financial Accounting Standards Board amended the disclosure requirements regarding the reporting of amounts reclassified out of accumulated other comprehensive income. The amendment does not change the current requirement for reporting net income or other comprehensive income, but requires additional disclosures about significant amounts reclassified out of accumulated other comprehensive income including the effect of the reclassification on the related net income line items. This amendment was adopted prospectively by the Company effective January 1, 2013 and is not expected to have a significant impact on the Company’s financial statements as the requirements are disclosure only in nature.
	Use of Estimates. The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.

REVENUE_RECOGNITION_AND_SIGNIF

REVENUE RECOGNITION AND SIGNIFICANT COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS	9 Months Ended
	Sep. 30, 2013
Organization Consolidation And Presentation Of Financial Statements [Abstract]
REVENUE RECOGNITION AND SIGNIFICANT COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS	2. REVENUE RECOGNITION AND SIGNIFICANT COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS
	Revenue Recognition Policy.
	Revenues under collaborative agreements and grants are recognized as research costs are incurred over the period specified in the related agreement or as the services are performed. These agreements are on a best-efforts basis, do not require scientific achievement as a performance obligation and provide for payment to be made when costs are incurred or the services are performed. All fees are nonrefundable to the collaborators. Prior to the revised multiple element guidance adopted by the Company on January 1, 2011, upfront, nonrefundable payments for license fees, grants, and advance payments for sponsored research revenues received in excess of amounts earned were classified as deferred revenue and recognized as income over the contract or development period. Estimating the duration of the development period includes continual assessment of development stages and regulatory requirements. If and when the Company enters into a new collaboration agreement or materially modifies an existing collaboration agreement, the Company will be required to apply the new multiple element guidance. Milestone payments are recognized as revenue upon achievement of pre-defined scientific events, which require substantive effort, and for which achievement of the milestone was not readily assured at the inception of the agreement.
	AbbVie Inc. (AbbVie). In June 2010, the Company announced an exclusive worldwide collaboration with AbbVie to develop and commercialize elagolix and all next-generation gonadotropin-releasing hormone (GnRH) antagonists (collectively, GnRH Compounds) for women’s and men’s health. AbbVie made an upfront payment of $75 million and has agreed to make additional development and regulatory event based payments of up to $480 million and up to an additional $50 million in commercial event based payments. The Company has assessed event based payments under the revised authoritative guidance for research and development milestones and determined that event based payments prior to commencement of a Phase III clinical study, as defined in the agreement, meet the definition of a milestone in accordance with authoritative guidance as (1) they are events that can only be achieved in part on the Company’s past performance, (2) there is substantive uncertainty at the date the arrangement was entered into that the event will be achieved and (3) they result in additional payments being due to the Company. Development and regulatory event based payments subsequent to the commencement of a Phase III clinical study, however, currently do not meet these criteria as their achievement is based on the performance of AbbVie. No milestone payments were recognized during the periods presented.
	Under the terms of the agreement, AbbVie is responsible for all third-party development, marketing and commercialization costs. The Company received funding for certain internal collaboration expenses, which included reimbursement from AbbVie for internal and external expenses related to the GnRH Compounds, through the end of 2012. The Company will be entitled to a percentage of worldwide sales of GnRH Compounds for the longer of ten years or the life of the related patent rights. Under the terms of the Company’s agreement with AbbVie, the collaboration effort between the parties to advance GnRH Compounds towards commercialization was governed by a joint development committee with representatives from both the Company and AbbVie. The Company’s participation in the joint development committee was determined to be a substantive deliverable under the contract, and therefore, the upfront payment was deferred and recognized over the term of the joint development committee, which was completed, as scheduled, in December 2012. AbbVie may terminate the collaboration at its discretion upon 180 days’ written notice to the Company. In such event, the Company would be entitled to specified payments for ongoing clinical development and related activities and all GnRH Compound product rights would revert to the Company.
	During the three and nine months ended September 30, 2013 and 2012, revenues recognized under the collaboration agreement with AbbVie were as follows (in millions):
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2013		2012		2013		2012
	Amortization of up-front license fees	$	—	$	7.3	$	—	$	21.8
	Sponsored research and development		—		1.4	$	—	$	4
	Revenues recognized under the AbbVie collaboration agreement	$	—	$	8.7	$	—	$	25.8
	Boehringer Ingelheim International GmbH (Boehringer Ingelheim). In June 2010, the Company announced a worldwide collaboration with Boehringer Ingelheim to research, develop and commercialize small molecule GPR119 agonists for the treatment of Type II diabetes and other indications. Under the terms of the Company’s agreement with Boehringer Ingelheim, the Company and Boehringer Ingelheim worked jointly, during a two year collaborative research period which ended in June 2012, to identify and advance GPR119 agonist candidates into preclinical development. Following the collaborative research period, Boehringer Ingelheim is responsible for the global development and commercialization of potential GPR119 agonist products, if any. The Company received a $10 million upfront payment, and received research funding to support discovery efforts. Boehringer Ingelheim agreed to make payments of up to approximately $3 million in additional preclinical milestone payments and payments of up to approximately $223 million in clinical development and commercial event based payments. The Company has assessed milestones under the revised authoritative guidance for research and development milestones and determined that the preclinical milestone payments, as defined in the agreement, meet the definition of a milestone as (1) they are events that can only be achieved in part on the Company’s performance or upon the occurrence of a specific outcome resulting from the Company’s performance, (2) there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved and (3) they result in additional payments being due to the Company. Clinical development and commercial milestone payments, however, currently do not meet these criteria as their achievement is solely based on the performance of Boehringer Ingelheim. No milestone payments were recognized during the periods presented. The Company will be entitled to a percentage of any future worldwide sales of GPR119 agonists. Under the terms of the agreement, the collaboration effort between the parties to identify and advance GPR119 agonist candidates into preclinical development was initially governed by a steering committee with representatives from both the Company and Boehringer Ingelheim; provided, however, that final decision making authority rested with Boehringer Ingelheim. The Company’s participation in the steering committee was determined to be a substantive deliverable under the contract, and therefore, the upfront payment was deferred and recognized over the two-year term of the steering committee which was completed, as scheduled, in June 2012. Boehringer Ingelheim may terminate the agreement at its discretion upon prior written notice to the Company. In such event, the Company may be entitled to specified payments and product rights would revert to the Company.
	During the three and nine months ended September 30, 2013 and 2012, revenues recognized under the collaboration agreement with Boehringer Ingelheim were as follows (in millions):
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2013		2012		2013		2012
	Amortization of up-front license fees	$	—	$	—	$	—	$	2.2
	Sponsored research and development		—		—	$	—	$	1
	Revenues recognized under the Boehringer Ingelheim collaboration agreement	$	—	$	—	$	—	$	3.2

INVESTMENTS

INVESTMENTS	9 Months Ended
	Sep. 30, 2013
Investments Schedule [Abstract]
INVESTMENTS	3. INVESTMENTS
	Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in comprehensive loss. The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization is included in interest income. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on available-for-sale securities are included in other income or expense. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income.
	Investments consisted of the following (in thousands):
			September 30,		December 31,
			2013		2012
	Certificates of deposit		$	13,163	$	12,434
	Commercial paper			12,094		19,695
	Corporate debt securities			89,940		77,610
	Securities of government sponsored entities			7,500		—
	Total investments		$	122,697	$	109,739
	The following is a summary of investments classified as available-for-sale securities (in thousands):
			Contractual		Amortized			Gross		Gross			Aggregate
			Maturity		Cost			Unrealized		Unrealized			Estimated
			(in years)					Gains(1)		Losses(1)			Fair
													Value
	September 30, 2013:
	Classified as current assets:
	Certificates of deposit			Less than 1	$	12,938		$	—	$	(16	)	$	12,922
	Commercial paper			Less than 1		12,094			2		(2	)		12,094
	Corporate debt securities			Less than 1		89,499			24		(17	)		89,506
	Securities of government sponsored entities			Less than 1		7,500			—		—			7,500
	Total short-term available for sale securities				$	122,031		$	26	$	(35	)	$	122,022
	Classified as long-term assets:
	Certificates of deposit			1 to 2		240			1		—			241
	Corporate debt securities			1 to 2		435			—		(1	)		434
	Total long-term available for sale securities					675			1		(1	)		675
	Total available-for-sale securities				$	122,706		$	27	$	(36	)	$	122,697
	December 31, 2012:
	Classified as current assets:
	Certificates of deposit			Less than 1	$	11,960		$	—	$	(6	)	$	11,954
	Commercial paper			Less than 1		19,713			—		(18	)		19,695
	Corporate debt securities			Less than 1		77,588			33		(11	)		77,610
	Total short-term available-for-sale securities				$	109,261		$	33	$	(35	)	$	109,259
	Classified as non-current assets:
	Certificates of deposit			1 to 2		480			—		—			480
	Total long-term available-for-sale securities					480			—		—			480
	Total available-for-sale securities				$	109,741		$	33	$	(35	)	$	109,739
	-1	Unrealized gains and losses are included in other comprehensive loss.
	The following table presents information about available-for-sale investments in an unrealized loss position but were not deemed to be other than temporarily impaired (in thousands):
			Less Than 12 Months					12 Months or Greater					Total
			Estimated		Unrealized			Estimated		Unrealized			Estimated		Unrealized
			Fair		Losses			Fair		Losses			Fair		Losses
			Value					Value					Value
	September 30, 2013:
	Certificates of deposit		$	11,993	$	(16	)	$	—	$	—		$	11,993	$	(16	)
	Corporate debt securities			42,885		(18	)		—		—			42,885		(18	)
	Commercial paper			2,495		(2	)		—		—			2,495		(2	)
	Total		$	57,373	$	(36	)	$	—	$	—		$	57,373	$	(36	)
	December 31, 2012:
	Certificates of deposit		$	10,273	$	(6	)	$	—	$	—		$	10,273	$	(6	)
	Commercial paper			19,695		(18	)		—		—			19,695		(18	)
	Corporate debt securities			37,524		(11	)		—		—			37,524		(11	)
	Total		$	67,492	$	(35	)	$	—	$	—		$	67,492	$	(35	)

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	4. FAIR VALUE MEASUREMENTS
	Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:
	Level 1:	Observable inputs such as quoted prices in active markets;
	Level 2:	Inputs include quoted prices for similar instruments in active markets and/or quoted prices for identical or similar instruments in markets that are not active near the measurement date; and
	Level 3:	Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
	The Company classifies its cash equivalents and available for sale investments within Level 1 or Level 2. The Company’s financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities, are carried at cost, which management believes approximates fair value and would classify these financial instruments within Level 1 of the fair value hierarchy because of the short-term maturity of these instruments.
	The fair value of the Company’s high quality investment grade corporate debt securities is determined using proprietary valuation models and analytical tools. These valuation models and analytical tools use market pricing or prices for similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids and/or offers. The Company did not reclassify any investments between levels in the fair value hierarchy during the three and nine months ended September 30, 2013.
	The Company’s assets which are measured at fair value on a recurring basis as of September 30, 2013 and December 31, 2012 were determined using the inputs described above (in millions):
					Fair Value Measurements Using
		Carrying			Quoted Prices in			Significant Other			Significant
		Value			Active Markets for			Observable Inputs			Unobservable Inputs
					Identical Assets			(Level 2)			(Level 3)
					(Level 1)
	September 30, 2013:
	Classified as current assets:
	Cash and money market funds	$	34.5		$	34.5		$	—		$	—
	Certificates of deposit		12.9			12.9			—			—
	Commercial paper		12.1			—			12.1			—
	Corporate bonds		89.9			—			89.9			—
	Securities of government sponsored entities		7.5			—			7.5			—
	Subtotal		156.9			47.4			109.5			—
	Classified as long-term assets:
	Certificates of deposit		4.6			4.6			—			—
	Corporate bonds		0.4			—			0.4			—
	Total		161.9			52			109.9			—
	Less cash, cash equivalents and restricted cash		(39.2	)		(38.8	)		(0.4	)		—
	Total investments	$	122.7		$	13.2		$	109.5		$	—
	December 31, 2012:
	Classified as current assets:
	Cash and money market funds	$	53.2		$	53.2		$	—		$	—
	Certificates of deposit		16.2			16.2			—			—
	Commercial paper		25.7			—			25.7			—
	Corporate bonds		82.2			—			82.2			—
	Subtotal		177.3			69.4			107.9			—
	Classified as long-term assets:
	Certificates of deposit		0.5			0.5			—			—
	Total		177.8			69.9			107.9			—
	Less cash, cash equivalents and restricted cash		(68.1	)		(57.5	)		(10.6	)		—
	Total investments	$	109.7		$	12.4		$	97.3		$	—

SHAREBASED_COMPENSATION

SHARE-BASED COMPENSATION	9 Months Ended
	Sep. 30, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
SHARE-BASED COMPENSATION	5. SHARE-BASED COMPENSATION
	The compensation expense related to the Company’s share-based compensation arrangements has been included in the condensed consolidated statements of comprehensive loss as follows (in millions):
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013		2012
	General and administrative	$	0.9		$	0.7		$	2.6	$	2.1
	Research and development		0.8			0.7		$	2.5	$	2.1
	Total share-based compensation expense	$	1.7		$	1.4		$	5.1	$	4.2
	The fair value of equity instruments that are ultimately expected to vest, net of estimated forfeitures, are recognized and amortized on a straight-line basis over the requisite service period. The Company estimates forfeiture rates for equity awards based on past behavior for similar equity awards with further consideration given to the class of employees to whom the equity awards were granted.
	As of September 30, 2013, total unrecognized estimated compensation cost related to non-vested stock options and non-vested restricted stock units (RSUs) granted prior to that date was $10.4 million and $2.7 million, respectively, which is expected to be recognized over a weighted average period of approximately 2.2 years and 3.3 years, respectively.
	During the nine months ended September 30, 2013 and 2012, stock options to purchase approximately 0.9 million and 0.1 million shares of the Company’s common stock were exercised, respectively. The cash received by the Company from stock option exercises during the nine months ended September 30, 2013 and 2012 was approximately $5.3 million and $0.4 million, respectively. The Company also issued approximately 50,000 shares of common stock pursuant to the vesting of RSUs during the nine months ended September 30, 2012.
	Stock Option Assumptions
	The Company granted stock options to purchase approximately 0.8 million and 1.4 million shares of the Company’s common stock during the nine months ended September 30, 2013 and 2012, respectively. The Company did not grant any stock options during the three months ended September 30, 2013. These stock options generally vest monthly over a four-year period. The exercise price of all stock options granted during the nine months ended September 30, 2013 and 2012 was equal to the closing price of the Company’s common stock on the date of grant. The estimated fair value of each stock option granted was determined on the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions for the stock option grants:
		Three Months			Nine Months
		Ended			Ended
		September 30,			September 30,
		2013		2012	2013		2012
	Risk-free interest rate	—		0.90%	1.40%		1.30%
	Expected volatility of common stock	—		72.10%	75.80%		79.40%
	Dividend yield	—		0.00%	0.00%		0.00%
	Expected option term	—		6 years	7.3 years		6.8 years
	The Black-Scholes option-pricing model incorporates various and highly sensitive assumptions including expected volatility, expected term and interest rates. The expected volatility is based on the historical volatility of the Company’s common stock over the most recent period commensurate with the estimated expected term of the Company’s stock options. The expected option term is estimated based on historical experience as well as the status of the employee. For example, directors and officers have a longer expected option term than all other employees. Additionally, recent grants of stock options have a contractual life of ten years, versus seven years for older option grants, and the vesting period for recent option grants has been extended to four years, which together have also resulted in an increase in the expected option term over time. The risk-free rate for periods within the contractual life of the option is based upon observed interest rates appropriate for the expected term of the Company’s employee stock options. The Company has never declared or paid dividends and has no plans to do so in the foreseeable future. For the nine months ended September 30, 2013 and 2012, share-based compensation expense related to stock options was $4.5 million and $4.2 million, respectively.
	Restricted Stock Units
	The Company granted RSUs covering approximately 0.4 million shares of its common stock to its employees during the nine months ended September 30, 2013. These RSUs vest on an annual basis over a four year period. The fair value of RSUs is estimated based on the closing sale price of the Company’s common stock on the date of issuance. For the nine months ended September 30, 2013, share-based compensation expense related to RSUs was $0.6 million.

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY	9 Months Ended
	Sep. 30, 2013
Equity [Abstract]
STOCKHOLDERS' EQUITY	6. STOCKHOLDERS’ EQUITY
	Equity Financing
	In January 2012, the Company completed a public offering of common stock in which the Company sold 10.9 million shares of its common stock at an offering price of $8.10 per share. The shares were sold pursuant an effective shelf registration statement with the SEC. The net proceeds generated from this transaction, after underwriting discounts and commissions and offering costs, were approximately $83.0 million.
	Shelf Registration Statements
	In December 2012, the SEC declared effective a shelf registration statement filed by the Company in November 2012. The shelf registration statement allows the Company to issue shares of its common stock from time to time for an aggregate initial offering price of up to $150 million.
	In December 2010, the SEC declared effective a shelf registration statement filed by the Company earlier in that month. The shelf registration statement allows the Company to issue shares of its common stock from time to time for an aggregate initial offering price of up to $125 million. As of September 30, 2013, the Company had approximately $37 million still available under this shelf registration statement. This shelf registration statement will expire in December 2013.
	The specific terms of future offerings, if any, under a shelf registration statement would be established at the time of such offerings.

REAL_ESTATE

REAL ESTATE	9 Months Ended
	Sep. 30, 2013
Leases [Abstract]
REAL ESTATE	7. REAL ESTATE
	In December 2007, the Company closed the sale of its facility and associated real property for a purchase price of $109 million. Concurrent with the sale, the Company retired the entire $47.7 million in mortgage debt previously outstanding with respect to the facility and associated real property, and received cash of $61.0 million net of transaction costs and debt retirement.
	Upon the closing of the sale of the facility and associated real property, the Company entered into a lease agreement (Lease) with DMH Campus Investors, LLC (DMH) whereby it leased back for an initial term of 12 years its corporate headquarters comprised of two buildings located at 12790 El Camino Real (Front Building) and 12780 El Camino Real (Rear Building) in San Diego, California. The Company also entered into a series of lease amendments (Amendments), beginning in late 2008, through which it vacated the Front Building, but continues to occupy the Rear Building. The ultimate result of this real estate sale was a net gain of $39.1 million which was deferred in accordance with authoritative guidance. The Company recognized $2.3 million of the deferred gain during each of the nine month periods ended September 30, 2013 and 2012, and will recognize the remaining $21.7 million of the deferred gain over the initial Lease term which will expire at the end of 2019.
	Under the terms of the Lease and the Amendments, the Company pays base annual rent (subject to an annual fixed percentage increase), plus a 3.5% annual management fee, property taxes and other normal and necessary expenses associated with the Lease such as utilities, repairs and maintenance. In lieu of a cash security deposit under the Lease, Wells Fargo Bank, N.A. issued on the Company’s behalf a letter of credit in the amount of $4.2 million, which is secured by a deposit of equal amount with the same bank. The Company also has the right to extend the Lease for two consecutive ten-year terms.
	In December 2010, the Company entered into a sublease agreement (Sublease) for approximately 16,000 square feet of the Rear Building. The Sublease is expected to result in approximately $0.6 million of rental income per year over the three year term of the Sublease and is recorded as an offset to rent expense. The Sublease provides an option to extend for two one-year renewal periods. The income generated under the Sublease is lower than the Company’s financial obligation under the Lease for the Rear Building with DMH, as determined on a per square foot basis. Consequently, at December 31, 2010 the Company was required to record a cease-use liability for the net present value estimated difference between the expected income to be generated under the Sublease and future subleases and the Lease obligation over the remaining term of the Lease for the space that is occupied by the subtenant. This transaction resulted in $2.5 million of gross cease-use expense, and a reversal of $173,000 in associated deferred rent, each being recorded in December 2010. In August 2012, the Company extended the terms of the Sublease and increased the leased square footage to approximately 17,000 square feet. This transaction resulted in approximately $150,000 of gross cease-use expense, and a reversal of $15,000 in associated deferred rent, each being recorded in September 2012.
	In September 2011, the Company entered into a second sublease agreement (Second Sublease) for approximately 3,300 square feet of space in the Rear Building. The Second Sublease is expected to result in approximately $0.1 million in rental income per year over the three year term and is recorded as an offset to rent expense. The Second Sublease provides an option to extend for a one-year renewal period. Similar to the Sublease, the Second Sublease resulted in $0.3 million of gross cease-use expense, and a reversal of $47,000 in associated deferred rent, each being recorded in September 2011.
	In November 2012, the Company entered into a third sublease agreement (Third Sublease) for approximately 14,000 square feet of space in the Rear Building. The Third Sublease is expected to result in approximately $0.5 million in rental income per year over the three and a half year term and is recorded as an offset to rent expense. The Third Sublease provides the subtenant with an option to extend the term for two one-year renewal periods. Similar to the previous subleases, the Third Sublease resulted in $1.2 million of gross cease-use expense, and a reversal of $250,000 in associated deferred rent, each being recorded in December 2012.
	At September 30, 2013 and 2012, the Company had recorded in its condensed consolidated balance sheet an aggregate cease-use liability related to the Sublease (as amended), the Second Sublease and the Third Sublease of $3.2 million and $2.5 million, respectively.
	The following table sets forth changes to the accrued cease-use liability during the three and nine months ended September 30, 2013 and 2012 (in thousands):
			Three Months Ended						Nine Months Ended
			September 30,						September 30,
			2013			2012			2013			2012
	Beginning balance		$	3,295		$	2,463		$	3,686		$	2,592
	Impact of sublease cease-use charges (1)			—			150			—			150
	Payments			(97	)		(64	)		(488	)		(193	)
	Ending balance		$	3,198		$	2,549		$	3,198		$	2,549
	-1	Total cease-use expense in 2012 was offset by the related adjustment to deferred rent of approximately $15,000

LOSS_PER_COMMON_SHARE

LOSS PER COMMON SHARE	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]
LOSS PER COMMON SHARE	8. LOSS PER COMMON SHARE
	The Company computes basic net loss per share using the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss for the period by the weighted average number of common and common equivalent shares outstanding during the period. Additionally, potentially dilutive securities, composed of incremental common shares issuable upon the exercise of stock options and the vesting of RSUs, are excluded from the diluted loss per share calculation because of their anti-dilutive effect.
	For the three and nine months ended September 30, 2013, the Company realized a net loss of $11.1 million and $35.4 million, respectively. Potentially dilutive securities totaled approximately 2.5 million and 2.2 million for the three and nine months ended September 30, 2013, respectively. Options to purchase approximately 0.1 million and 0.3 million shares of common stock were outstanding during the three and nine months ended September 30, 2013, respectively, with an exercise price greater than the average market price of the underlying common shares.
	For the three and nine months ended September 30, 2012, the Company realized a net loss of $3.1 million and $4.5 million, respectively. Potentially dilutive securities excluded from the historical diluted loss per share totaled 1.3 million for each of the three and nine months ended September 30, 2012, respectively. Options to purchase 2.3 million shares of common stock were outstanding during each of the three and nine months ended September 30, 2012, with an exercise price greater than the average market price of the underlying common shares.

RESEARCH_AND_DEVELOPMENT

RESEARCH AND DEVELOPMENT	9 Months Ended
	Sep. 30, 2013
Research And Development [Abstract]
RESEARCH AND DEVELOPMENT	9. RESEARCH AND DEVELOPMENT
	Research and development (R&D) expenses consists primarily of salaries, payroll taxes, employee benefits, and share-based compensation charges, for those individuals involved in ongoing R&D efforts; as well as scientific contractor fees, preclinical and clinical trial costs, R&D facilities costs, laboratory supply costs, and depreciation of scientific equipment. All such costs are charged to R&D expense as incurred. These expenses result from the Company’s independent R&D efforts as well as efforts associated with collaborations and in-licensing arrangements. In addition, the Company funds R&D at other companies and research institutions under agreements, which are generally cancelable. The Company reviews and accrues clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of patient studies and other events. The Company follows this method since reasonably dependable estimates of the costs applicable to various stages of a research agreement or clinical trial can be made. Accrued clinical costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2013
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	10. SUBSEQUENT EVENTS
	The Company has evaluated all subsequent events that have occurred after the date of the accompanying financial statements and determined that there were no events or transactions occurring during this subsequent event reporting period which require recognition or disclosure in the Company’s financial statements.

ORGANIZATION_AND_SIGNIFICANT_A1

ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial information and with the instructions of the Securities and Exchange Commission (SEC) on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of the Company’s financial position and of the results of operations and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary.
	These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2012 included in the Company’s Annual Report on Form 10-K filed with the SEC. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year. The balance sheet at December 31, 2012 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.
Impact of Recently Issued Accounting Standards	Impact of Recently Issued Accounting Standards. In February 2013, the Financial Accounting Standards Board amended the disclosure requirements regarding the reporting of amounts reclassified out of accumulated other comprehensive income. The amendment does not change the current requirement for reporting net income or other comprehensive income, but requires additional disclosures about significant amounts reclassified out of accumulated other comprehensive income including the effect of the reclassification on the related net income line items. This amendment was adopted prospectively by the Company effective January 1, 2013 and is not expected to have a significant impact on the Company’s financial statements as the requirements are disclosure only in nature.
Use of Estimates	Use of Estimates. The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.
Revenue Recognition Policy	Revenue Recognition Policy.
	Revenues under collaborative agreements and grants are recognized as research costs are incurred over the period specified in the related agreement or as the services are performed. These agreements are on a best-efforts basis, do not require scientific achievement as a performance obligation and provide for payment to be made when costs are incurred or the services are performed. All fees are nonrefundable to the collaborators. Prior to the revised multiple element guidance adopted by the Company on January 1, 2011, upfront, nonrefundable payments for license fees, grants, and advance payments for sponsored research revenues received in excess of amounts earned were classified as deferred revenue and recognized as income over the contract or development period. Estimating the duration of the development period includes continual assessment of development stages and regulatory requirements. If and when the Company enters into a new collaboration agreement or materially modifies an existing collaboration agreement, the Company will be required to apply the new multiple element guidance. Milestone payments are recognized as revenue upon achievement of pre-defined scientific events, which require substantive effort, and for which achievement of the milestone was not readily assured at the inception of the agreement.

REVENUE_RECOGNITION_AND_SIGNIF1

REVENUE RECOGNITION AND SIGNIFICANT COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS (Tables)	9 Months Ended
	Sep. 30, 2013
Boehringer Ingelheim International GmbH
Revenues Recognized under Collaboration Agreement	During the three and nine months ended September 30, 2013 and 2012, revenues recognized under the collaboration agreement with Boehringer Ingelheim were as follows (in millions):
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2013		2012		2013		2012
	Amortization of up-front license fees	$	—	$	—	$	—	$	2.2
	Sponsored research and development		—		—	$	—	$	1
	Revenues recognized under the Boehringer Ingelheim collaboration agreement	$	—	$	—	$	—	$	3.2
AbbVie
Revenues Recognized under Collaboration Agreement	During the three and nine months ended September 30, 2013 and 2012, revenues recognized under the collaboration agreement with AbbVie were as follows (in millions):
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2013		2012		2013		2012
	Amortization of up-front license fees	$	—	$	7.3	$	—	$	21.8
	Sponsored research and development		—		1.4	$	—	$	4
	Revenues recognized under the AbbVie collaboration agreement	$	—	$	8.7	$	—	$	25.8

INVESTMENTS_Tables

INVESTMENTS (Tables)	9 Months Ended
	Sep. 30, 2013
Investments Schedule [Abstract]
Investments	Investments consisted of the following (in thousands):
			September 30,		December 31,
			2013		2012
	Certificates of deposit		$	13,163	$	12,434
	Commercial paper			12,094		19,695
	Corporate debt securities			89,940		77,610
	Securities of government sponsored entities			7,500		—
	Total investments		$	122,697	$	109,739
Summary of Investments Classified as Available-For-Sale Securities	The following is a summary of investments classified as available-for-sale securities (in thousands):
			Contractual		Amortized			Gross		Gross			Aggregate
			Maturity		Cost			Unrealized		Unrealized			Estimated
			(in years)					Gains(1)		Losses(1)			Fair
													Value
	September 30, 2013:
	Classified as current assets:
	Certificates of deposit			Less than 1	$	12,938		$	—	$	(16	)	$	12,922
	Commercial paper			Less than 1		12,094			2		(2	)		12,094
	Corporate debt securities			Less than 1		89,499			24		(17	)		89,506
	Securities of government sponsored entities			Less than 1		7,500			—		—			7,500
	Total short-term available for sale securities				$	122,031		$	26	$	(35	)	$	122,022
	Classified as long-term assets:
	Certificates of deposit			1 to 2		240			1		—			241
	Corporate debt securities			1 to 2		435			—		(1	)		434
	Total long-term available for sale securities					675			1		(1	)		675
	Total available-for-sale securities				$	122,706		$	27	$	(36	)	$	122,697
	December 31, 2012:
	Classified as current assets:
	Certificates of deposit			Less than 1	$	11,960		$	—	$	(6	)	$	11,954
	Commercial paper			Less than 1		19,713			—		(18	)		19,695
	Corporate debt securities			Less than 1		77,588			33		(11	)		77,610
	Total short-term available-for-sale securities				$	109,261		$	33	$	(35	)	$	109,259
	Classified as non-current assets:
	Certificates of deposit			1 to 2		480			—		—			480
	Total long-term available-for-sale securities					480			—		—			480
	Total available-for-sale securities				$	109,741		$	33	$	(35	)	$	109,739
	-1	Unrealized gains and losses are included in other comprehensive loss.
Available-For-Sale Investments in Unrealized Loss Position	The following table presents information about available-for-sale investments in an unrealized loss position but were not deemed to be other than temporarily impaired (in thousands):
			Less Than 12 Months					12 Months or Greater					Total
			Estimated		Unrealized			Estimated		Unrealized			Estimated		Unrealized
			Fair		Losses			Fair		Losses			Fair		Losses
			Value					Value					Value
	September 30, 2013:
	Certificates of deposit		$	11,993	$	(16	)	$	—	$	—		$	11,993	$	(16	)
	Corporate debt securities			42,885		(18	)		—		—			42,885		(18	)
	Commercial paper			2,495		(2	)		—		—			2,495		(2	)
	Total		$	57,373	$	(36	)	$	—	$	—		$	57,373	$	(36	)
	December 31, 2012:
	Certificates of deposit		$	10,273	$	(6	)	$	—	$	—		$	10,273	$	(6	)
	Commercial paper			19,695		(18	)		—		—			19,695		(18	)
	Corporate debt securities			37,524		(11	)		—		—			37,524		(11	)
	Total		$	67,492	$	(35	)	$	—	$	—		$	67,492	$	(35	)

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]
Assets Measured at Fair Value on Recurring Basis	The Company’s assets which are measured at fair value on a recurring basis as of September 30, 2013 and December 31, 2012 were determined using the inputs described above (in millions):
					Fair Value Measurements Using
		Carrying			Quoted Prices in			Significant Other			Significant
		Value			Active Markets for			Observable Inputs			Unobservable Inputs
					Identical Assets			(Level 2)			(Level 3)
					(Level 1)
	September 30, 2013:
	Classified as current assets:
	Cash and money market funds	$	34.5		$	34.5		$	—		$	—
	Certificates of deposit		12.9			12.9			—			—
	Commercial paper		12.1			—			12.1			—
	Corporate bonds		89.9			—			89.9			—
	Securities of government sponsored entities		7.5			—			7.5			—
	Subtotal		156.9			47.4			109.5			—
	Classified as long-term assets:
	Certificates of deposit		4.6			4.6			—			—
	Corporate bonds		0.4			—			0.4			—
	Total		161.9			52			109.9			—
	Less cash, cash equivalents and restricted cash		(39.2	)		(38.8	)		(0.4	)		—
	Total investments	$	122.7		$	13.2		$	109.5		$	—
	December 31, 2012:
	Classified as current assets:
	Cash and money market funds	$	53.2		$	53.2		$	—		$	—
	Certificates of deposit		16.2			16.2			—			—
	Commercial paper		25.7			—			25.7			—
	Corporate bonds		82.2			—			82.2			—
	Subtotal		177.3			69.4			107.9			—
	Classified as long-term assets:
	Certificates of deposit		0.5			0.5			—			—
	Total		177.8			69.9			107.9			—
	Less cash, cash equivalents and restricted cash		(68.1	)		(57.5	)		(10.6	)		—
	Total investments	$	109.7		$	12.4		$	97.3		$	—

SHAREBASED_COMPENSATION_Tables

SHARE-BASED COMPENSATION (Tables)	9 Months Ended
	Sep. 30, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Compensation Expenses Related to Share Based Compensation	The compensation expense related to the Company’s share-based compensation arrangements has been included in the condensed consolidated statements of comprehensive loss as follows (in millions):
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013		2012
	General and administrative	$	0.9		$	0.7		$	2.6	$	2.1
	Research and development		0.8			0.7		$	2.5	$	2.1
	Total share-based compensation expense	$	1.7		$	1.4		$	5.1	$	4.2
Weighted-Average Assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model	The estimated fair value of each stock option granted was determined on the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions for the stock option grants:
		Three Months			Nine Months
		Ended			Ended
		September 30,			September 30,
		2013		2012	2013		2012
	Risk-free interest rate	—		0.90%	1.40%		1.30%
	Expected volatility of common stock	—		72.10%	75.80%		79.40%
	Dividend yield	—		0.00%	0.00%		0.00%
	Expected option term	—		6 years	7.3 years		6.8 years

REAL_ESTATE_Tables

REAL ESTATE (Tables)	9 Months Ended
	Sep. 30, 2013
Leases [Abstract]
Changes to Accrued Cease-Use Liability	The following table sets forth changes to the accrued cease-use liability during the three and nine months ended September 30, 2013 and 2012 (in thousands):
			Three Months Ended						Nine Months Ended
			September 30,						September 30,
			2013			2012			2013			2012
	Beginning balance		$	3,295		$	2,463		$	3,686		$	2,592
	Impact of sublease cease-use charges (1)			—			150			—			150
	Payments			(97	)		(64	)		(488	)		(193	)
	Ending balance		$	3,198		$	2,549		$	3,198		$	2,549
	-1	Total cease-use expense in 2012 was offset by the related adjustment to deferred rent of approximately $15,000

Recovered_Sheet1

Revenue Recognition and Significant Collaborative Research and Development Agreements - Additional Information (Detail) (USD $)	1 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2010	Dec. 31, 2012
AbbVie
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative agreement upfront payment received	$75
Collaborative arrangement right description		The Company received funding for certain internal collaboration expenses which included reimbursement from AbbVie for internal and external expenses related to the GnRH Compounds through the end of 2012. The Company will be entitled to a percentage of worldwide sales of GnRH Compounds for the longer of ten years or the life of the related patent rights.
Patent rights period		10 years
Collaboration termination notice period		180 days
AbbVie | Development and regulatory event based payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative agreement maximum additional payment to receive	480
AbbVie | Commercial event based payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative agreement maximum additional payment to receive	50
Boehringer Ingelheim International GmbH
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative agreement upfront payment received	10
Collaborative research period	2 years
Deferred upfront payment recognition period	2 years
Boehringer Ingelheim International GmbH | Preclinical milestone payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative agreement maximum additional payment to receive	3
Boehringer Ingelheim International GmbH | Clinical development and commercial event based payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative agreement maximum additional payment to receive	$223

Revenues_Recognized_under_Coll

Revenues Recognized under Collaboration Agreement with AbbVie Inc. (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Sponsored research and development		$1,369,000		$4,938,000
AbbVie
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Amortization of up-front license fees		7,300,000		21,800,000
Sponsored research and development		1,400,000		4,000,000
Revenues recognized under collaboration agreement		$8,700,000		$25,800,000

Revenues_Recognized_under_Coll1

Revenues Recognized under Collaboration Agreement with Boehringer Ingelheim (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Sponsored research and development		$1,369,000		$4,938,000
Boehringer Ingelheim International GmbH
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Amortization of up-front license fees				2,200,000
Sponsored research and development				1,000,000
Revenues recognized under collaboration agreement				$3,200,000

Investments_Detail

Investments (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Schedule of Investments [Line Items]
Investments	$122,697	$109,739
Certificates of deposit
Schedule of Investments [Line Items]
Investments	13,163	12,434
Commercial paper
Schedule of Investments [Line Items]
Investments	12,094	19,695
Corporate debt securities
Schedule of Investments [Line Items]
Investments	89,940	77,610
Securities of government sponsored entities
Schedule of Investments [Line Items]
Investments	$7,500

Summary_of_Investments_Classif

Summary of Investments Classified as Available-For-Sale Securities (Detail) (USD $)	9 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013		Dec. 31, 2012
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$122,706		$109,741
Gross Unrealized Gains	27	[1]	33	[1]
Gross Unrealized Losses	-36	[1]	-35	[1]
Aggregate Estimated Fair Value	122,697		109,739
Certificates of deposit
Schedule of Available-for-sale Securities [Line Items]
Aggregate Estimated Fair Value	13,163		12,434
Commercial paper
Schedule of Available-for-sale Securities [Line Items]
Aggregate Estimated Fair Value	12,094		19,695
Corporate debt securities
Schedule of Available-for-sale Securities [Line Items]
Aggregate Estimated Fair Value	89,940		77,610
Securities of government sponsored entities
Schedule of Available-for-sale Securities [Line Items]
Aggregate Estimated Fair Value	7,500
Short-term investments
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	122,031		109,261
Gross Unrealized Gains	26	[1]	33	[1]
Gross Unrealized Losses	-35	[1]	-35	[1]
Aggregate Estimated Fair Value	122,022		109,259
Short-term investments | Certificates of deposit
Schedule of Available-for-sale Securities [Line Items]
Available for sale securities contractual maturity	1 year		1 year
Amortized Cost	12,938		11,960
Gross Unrealized Gains		[1]		[1]
Gross Unrealized Losses	-16	[1]	-6	[1]
Aggregate Estimated Fair Value	12,922		11,954
Short-term investments | Commercial paper
Schedule of Available-for-sale Securities [Line Items]
Available for sale securities contractual maturity	1 year		1 year
Amortized Cost	12,094		19,713
Gross Unrealized Gains	2	[1]		[1]
Gross Unrealized Losses	-2	[1]	-18	[1]
Aggregate Estimated Fair Value	12,094		19,695
Short-term investments | Corporate debt securities
Schedule of Available-for-sale Securities [Line Items]
Available for sale securities contractual maturity	1 year		1 year
Amortized Cost	89,499		77,588
Gross Unrealized Gains	24	[1]	33	[1]
Gross Unrealized Losses	-17	[1]	-11	[1]
Aggregate Estimated Fair Value	89,506		77,610
Short-term investments | Securities of government sponsored entities
Schedule of Available-for-sale Securities [Line Items]
Available for sale securities contractual maturity	1 year
Amortized Cost	7,500
Gross Unrealized Gains		[1]
Gross Unrealized Losses		[1]
Aggregate Estimated Fair Value	7,500
Long-term investments
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	675		480
Gross Unrealized Gains	1	[1]		[1]
Gross Unrealized Losses	-1	[1]		[1]
Aggregate Estimated Fair Value	675		480
Long-term investments | Certificates of deposit
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	240		480
Gross Unrealized Gains	1	[1]		[1]
Gross Unrealized Losses		[1]		[1]
Aggregate Estimated Fair Value	241		480
Long-term investments | Certificates of deposit | Minimum
Schedule of Available-for-sale Securities [Line Items]
Available for sale securities contractual maturity	1 year		1 year
Long-term investments | Certificates of deposit | Maximum
Schedule of Available-for-sale Securities [Line Items]
Available for sale securities contractual maturity	2 years		2 years
Long-term investments | Corporate debt securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	435
Gross Unrealized Gains		[1]
Gross Unrealized Losses	-1	[1]
Aggregate Estimated Fair Value	$434
Long-term investments | Corporate debt securities | Minimum
Schedule of Available-for-sale Securities [Line Items]
Available for sale securities contractual maturity	1 year
Long-term investments | Corporate debt securities | Maximum
Schedule of Available-for-sale Securities [Line Items]
Available for sale securities contractual maturity	2 years
[1]	Unrealized gains and losses are included in other comprehensive loss.

AvailableForSale_Investments_i

Available-For-Sale Investments in Unrealized Loss Position (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]
Less Than 12 Months, Estimated Fair Value	$57,373	$67,492
Less Than 12 Months, Unrealized Losses	-36	-35
12 Month or Greater, Estimated Fair Value
12 Month or Greater, Unrealized Losses
Total Estimated Fair Value	57,373	67,492
Total Unrealized Losses	-36	-35
Certificates of deposit
Schedule of Available-for-sale Securities [Line Items]
Less Than 12 Months, Estimated Fair Value	11,993	10,273
Less Than 12 Months, Unrealized Losses	-16	-6
12 Month or Greater, Estimated Fair Value
12 Month or Greater, Unrealized Losses
Total Estimated Fair Value	11,993	10,273
Total Unrealized Losses	-16	-6
Corporate debt securities
Schedule of Available-for-sale Securities [Line Items]
Less Than 12 Months, Estimated Fair Value	42,885	37,524
Less Than 12 Months, Unrealized Losses	-18	-11
12 Month or Greater, Estimated Fair Value
12 Month or Greater, Unrealized Losses
Total Estimated Fair Value	42,885	37,524
Total Unrealized Losses	-18	-11
Commercial paper
Schedule of Available-for-sale Securities [Line Items]
Less Than 12 Months, Estimated Fair Value	2,495	19,695
Less Than 12 Months, Unrealized Losses	-2	-18
12 Month or Greater, Estimated Fair Value
12 Month or Greater, Unrealized Losses
Total Estimated Fair Value	2,495	19,695
Total Unrealized Losses	($2)	($18)

Assets_Measured_at_Fair_Value_

Assets Measured at Fair Value on Recurring Basis (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Fair Value, Measurements, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	$122.70	$109.70
Fair Value, Measurements, Recurring | Investments Including Cash Equivalents And Restricted Cash [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	161.9	177.8
Fair Value, Measurements, Recurring | Cash and Cash Equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	39.2	68.1
Short-term investments | Fair Value, Measurements, Recurring | Cash and money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	34.5	53.2
Short-term investments | Fair Value, Measurements, Recurring | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	12.9	16.2
Short-term investments | Fair Value, Measurements, Recurring | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	12.1	25.7
Short-term investments | Fair Value, Measurements, Recurring | Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	89.9	82.2
Short-term investments | Fair Value, Measurements, Recurring | Securities of government sponsored entities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	7.5
Short-term investments | Fair Value, Measurements, Recurring | Short Term Investments and Cash Equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	156.9	177.3
Long-term investments | Fair Value, Measurements, Recurring | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	4.6	0.5
Long-term investments | Fair Value, Measurements, Recurring | Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Value	0.4
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	13.2	12.4
Quoted Prices in Active Markets for Identical Assets (Level 1) | Investments Including Cash Equivalents And Restricted Cash [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	52	69.9
Quoted Prices in Active Markets for Identical Assets (Level 1) | Cash and Cash Equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	38.8	57.5
Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term investments | Cash and money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	34.5	53.2
Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term investments | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	12.9	16.2
Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term investments | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis
Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term investments | Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis
Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term investments | Securities of government sponsored entities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis
Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term investments | Short Term Investments and Cash Equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	47.4	69.4
Quoted Prices in Active Markets for Identical Assets (Level 1) | Long-term investments | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	4.6	0.5
Quoted Prices in Active Markets for Identical Assets (Level 1) | Long-term investments | Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	109.5	97.3
Significant Other Observable Inputs (Level 2) | Investments Including Cash Equivalents And Restricted Cash [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	109.9	107.9
Significant Other Observable Inputs (Level 2) | Cash and Cash Equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0.4	10.6
Significant Other Observable Inputs (Level 2) | Short-term investments | Cash and money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis
Significant Other Observable Inputs (Level 2) | Short-term investments | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis
Significant Other Observable Inputs (Level 2) | Short-term investments | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	12.1	25.7
Significant Other Observable Inputs (Level 2) | Short-term investments | Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	89.9	82.2
Significant Other Observable Inputs (Level 2) | Short-term investments | Securities of government sponsored entities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	7.5
Significant Other Observable Inputs (Level 2) | Short-term investments | Short Term Investments and Cash Equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	109.5	107.9
Significant Other Observable Inputs (Level 2) | Long-term investments | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis
Significant Other Observable Inputs (Level 2) | Long-term investments | Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis	0.4
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis
Significant Unobservable Inputs (Level 3) | Investments Including Cash Equivalents And Restricted Cash [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis
Significant Unobservable Inputs (Level 3) | Cash and Cash Equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis
Significant Unobservable Inputs (Level 3) | Short-term investments | Cash and money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis
Significant Unobservable Inputs (Level 3) | Short-term investments | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis
Significant Unobservable Inputs (Level 3) | Short-term investments | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis
Significant Unobservable Inputs (Level 3) | Short-term investments | Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis
Significant Unobservable Inputs (Level 3) | Short-term investments | Securities of government sponsored entities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis
Significant Unobservable Inputs (Level 3) | Short-term investments | Short Term Investments and Cash Equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis
Significant Unobservable Inputs (Level 3) | Long-term investments | Certificates of deposit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis
Significant Unobservable Inputs (Level 3) | Long-term investments | Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets on recurring basis

Compensation_Expense_Related_t

Compensation Expense Related to Share-Based Compensation (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense	$1.70	$1.40	$5.10	$4.20
General and Administrative Expense
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense	0.9	0.7	2.6	2.1
Research and Development Expense
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense	$0.80	$0.70	$2.50	$2.10

ShareBased_Compensation_Additi

Share-Based Compensation - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock option exercised			900,000	100,000
Cash received from stock option exercises			$5.30	$0.40
Common stock issued pursuant to the vesting of restricted stock units (RSUs)				50,000
Stock options granted	0		800,000	1,400,000
Stock vesting period			4 years
Stock option contractual life			10 years
Share based compensation expense	1.7	1.4	5.1	4.2
Scenario, Previously Reported
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock option contractual life			7 years
Stock Options
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Unrecognized compensation cost	10.4		10.4
Unrecognized compensation cost, weighted average period of recognition			2 years 2 months 12 days
Stock vesting period			4 years
Share based compensation expense			4.5	4.2
Restricted Stock Units (RSUs)
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Unrecognized compensation cost	2.7		2.7
Unrecognized compensation cost, weighted average period of recognition			3 years 3 months 18 days
Stock vesting period			4 years
Share based compensation expense			$0.60
Restricted stock units granted			400,000

WeightedAverage_Assumptions_fo

Weighted-Average Assumptions for Stock Option Grants using Black-Scholes Option-Pricing Model (Detail) (Stock Options)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate		0.90%	1.40%	1.30%
Expected volatility of common stock		72.10%	75.80%	79.40%
Dividend yield		0.00%	0.00%	0.00%
Expected option term		6 years	7 years 3 months 18 days	6 years 9 months 18 days

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	1 Months Ended	9 Months Ended
Share data in Millions, except Per Share data, unless otherwise specified	Jan. 31, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2010
				Shelf Registration	Shelf Registration	Shelf Registration
					Maximum	Maximum
Class of Stock [Line Items]
Common stock issued	10.9
Common stock, offering price	$8.10
Proceeds from common stock issuance	$83,000,000	$5,252,000	$83,414,000
Aggregate initial offering price of common stock					150,000,000	125,000,000
Common stock offering remaining value				$37,000,000
Shelf registration statement expire date				2013-12

Real_Estate_Additional_Informa

Real Estate - Additional Information (Detail) (USD $)

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Aug. 31, 2012

Dec. 31, 2010

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2007

Jun. 30, 2013

Dec. 31, 2012

Jun. 30, 2012

Dec. 31, 2011

Dec. 31, 2008

Sep. 30, 2012

Dec. 31, 2010

Sep. 30, 2011

Dec. 31, 2012

Nov. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2007

sqft

sqft

Sublease

Sublease

Second Sublease

Third Sublease

Third Sublease

Third Sublease

Third Sublease

Lease Back Type Transactions

sqft

sqft

Entity

RenewalOptions

Real Estate Properties [Line Items]

Sale of facility and associated real property

$109,000,000

Mortgage debt retired

47,700,000

Cash received net of transaction costs and debt retirement

61,000,000

Sale leaseback transaction term

The Company entered into a lease agreement (Lease) with DMH Campus Investors, LLC (DMH) whereby it leased back for an initial term of 12 years its corporate headquarters comprised of two buildings located at 12790 El Camino Real (Front Building) and 12780 El Camino Real (Rear Building) in San Diego, California. The Company also entered into a series of lease amendments (Amendments), beginning in late 2008, through which it vacated the Front Building, but continues to occupy the Rear Building.

Leaseback transaction lease period

12 years

Number of building leased

2

Net deferred gain on real estate sale

21,700,000

39,100,000

Deferred gain recognized

2,300,000

2,300,000

Deferred gain, initial lease expiration year

2019

Percentage of management fee included in the base annual rent

3.50%

Letter of credit

4,200,000

Lease extension period

10 years

Number of times to renew the lease contract

2

2

2

Subleased space (in square feet)

17,000

16,000

3,300

14,000

Sublease agreement, annual rental income

600,000

100,000

500,000

Sublease term

3 years

3 years

3 years 6 months

Renewal periods

1 year

1 year

1 year

Cease-use expense

135,000

135,000

150,000

2,500,000

300,000

1,200,000

Deferred rent reversed

15,000

15,000

173,000

47,000

250,000

Cease-use liability

$2,549,000

$3,198,000

$2,549,000

$3,295,000

$3,686,000

$2,463,000

$2,592,000

$3,200,000

$2,500,000

Changes_to_Accrued_CeaseUse_Li

Changes to Accrued Cease-Use Liability (Detail) (USD $)	3 Months Ended			9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012		Sep. 30, 2013	Sep. 30, 2012
Real Estate [Abstract]
Beginning balance	$3,295	$2,463		$3,686	$2,592
Impact of sublease cease-use charges		150	[1]		150	[1]
Payments	-97	-64		-488	-193
Ending balance	$3,198	$2,549		$3,198	$2,549
[1]	Total cease-use expense in 2012 was offset by the related adjustment to deferred rent of approximately $15,000

Changes_to_Accrued_CeaseUse_Li1

Changes to Accrued Cease-Use Liability (Parenthetical) (Detail) (USD $)	9 Months Ended
	Sep. 30, 2012
Real Estate [Abstract]
Deferred rent reversed	$15,000

Loss_Per_Common_Share_Addition

Loss Per Common Share - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data in Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Earnings Per Share [Abstract]
Net (loss) income	($11,131)	($3,078)	($35,448)	($4,465)
Potentially dilutive securities	2.5	1.3	2.2	1.3
Shares of common stock excluded from computation of diluted earnings per share outstanding	0.1	2.3	0.3	2.3